From Academic Discovery to Clinical Trials: Transitional Priorities
Moving a drug from academic discovery to clinical trials is one of the most critical phases in pharmaceutical development. Academic research often focuses on understanding disease mechanisms and identifying potential targets
Regulatory Pathways FDA and EMA – Are You Prepared for Ongoing AI Supervision?
Regulatory pathways in the United States and Europe are becoming more complex. The FDA and the EMA continue to raise expectations for data quality, transparency, and oversight. At the same time, regulators are expanding their use of advanced digital tools, including artificial intelligence, to review submissions, monitor compliance, and identify risk.
Pharma's Future: Addressing Political Challenges to DEI
As national debates over diversity, equity, and inclusion (DEI) continue to intensify, these conflicts are beginning to shape biomedical policy, clinical research, workforce development, and the long-term direction of American innovation.